Description
+ Include: 47 videos + 47 file sub vtt + 49 pdfs, size: 15.81 GB
+ Target Audience: hematologists and medical oncologists
+ Sample video: contact me for sample video
+ Information:
1. Overview
The Memorial Sloan Kettering Cancer Center 2026 Update in Hematology and Medical Oncology and 14th Annual Board Review is a four-day comprehensive course offering an in-depth, current review of the diagnosis, staging, and management of neoplastic diseases across both solid tumors and hematologic malignancies. Expert-led lectures cover a wide spectrum of disease-specific topics, including gastrointestinal, gynecologic, thoracic, head and neck, genitourinary, soft tissue and skin, and central nervous system oncology, in addition to hematologic oncology.
Course Date: Friday, March 13, 2026, 9:10 AM – Monday, March 16, 2026, 4:00 PM, Online
This course is designed for medical oncology professionals — including physicians, nurses, pharmacists, advanced practice providers, fellows, and residents — seeking a comprehensive update in Medical Oncology and Hematology.
2. Learning Objectives
- Define state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers
- Discuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice
- Prepare for ABIM examinations in medical oncology and hematology
3. Target Audience
Best for hematologists and medical oncologists who want comprehensive updates on the management of hematologic malignancies and solid tumors.
4. Topics
-
Acute Lymphocytic Leukemia
-
Acute Myeloid Leukemia
-
Anal and Rectal Cancers
-
Anticoagulation- Update on an Evolving Field
-
Apporach to the Bleeding Patient
-
Auto _Allo
-
Breast Cancer- Radiation Therapy
-
Breast Cancer- Surgery
-
CAR T Cell
-
Carcinoma of Unknown Primary
-
Central Nervous System Tumors
-
Chronic Lymphocytic Leukemia _Small Lymphocytic Lymphoma
-
Chronic Myelogenous Leukemia
-
Clinical Indications for Use of Blood Products and Associated Risks
-
Colon Cancer
-
Diffuse Large B-Cell Lymphoma _Mantle Cell Lymphoma _Burkitt Lymphoma
-
Esophageal and Gastric Cancers
-
Head and Neck, Thyroid, and Non-Melanoma Skin Cancers
-
Hemolytic Anemia
-
Hepatocellular Cancer and Cholangiocarcinoma
-
HER2-Positive Breast Cancer
-
Hereditary Cancer Genetics
-
Hodgkin Lymphoma_T Cell
-
Hormone Receptor-Positive Breast Cancer
-
Infectious Disease
-
Kidney Cancer
-
Low-Grade Non-Hodgkin Lymphoma
-
Melanoma
-
Mesothelioma
-
Myelodysplastic
-
Myeloma_Amyloid
-
Myeloproliferative Neoplasms
-
Non-Small Cell Lung Cancer
-
Ovarian Cancer
-
Pancreatic and Neuroendocrine Cancers
-
Pharmacology I_II
-
Prostate Cancer
-
Sarcoma
-
Sickle Cell Disease, Thalassemia
-
Small Cell Lung Cancer
-
Testis Cancer
-
Thrombocytopenia and ITP
-
Thrombotic Disorders
-
Transfusion Reactions
-
Triple-Negative Breast Cancer
-
Urothelial Cancer
-
Uterine, Cervix, and Other Gynecologic Cancers
- 2026 Post-Test HemOnc Board Review





Reviews
There are no reviews yet.